礼来公布Imlunestrant最新研究结果

Core Insights - Eli Lilly announced significant results from the Phase 3 EMBER-3 clinical trial of the oral estrogen receptor antagonist imlunestrant, showing a 38% reduction in the risk of disease progression or death in patients with ESR1 mutations compared to endocrine therapy [1][2] - The median progression-free survival (PFS) for imlunestrant was 5.5 months versus 3.8 months for endocrine therapy, with a hazard ratio (HR) of 0.62 [1] - The median overall survival (OS) was extended by 11.4 months, with imlunestrant showing 34.5 months compared to 23.1 months for the control group, achieving a HR of 0.60 [1] - In all patients, the combination of imlunestrant and abemaciclib reduced the risk of disease progression or death by 41%, with a trend towards improved overall survival and a delay in time to chemotherapy exceeding one year [1] Company and Industry Developments - The results were published in the Annals of Oncology and presented at the San Antonio Breast Cancer Symposium (SABCS) [2] - Eli Lilly's Executive Vice President and President of Oncology, Jake Van Naarden, emphasized the clinical benefits of imlunestrant in both monotherapy and combination therapy, reinforcing its position in the treatment landscape [2] - The company is encouraged by the potential of the all-oral combination treatment of imlunestrant and abemaciclib and has submitted relevant data to U.S. regulatory authorities for patients with ESR1 mutation metastatic breast cancer [2]